Gerdau S.A. Common Stock vs TransMedics Group Inc — how do they compare? Gerdau S.A. Common Stock trades at $5.09 (market cap $9.16B), while TransMedics Group Inc trades at $77.75 (market cap $2.74B). The key difference: Gerdau S.A. Common Stock is far larger — about 3.3× TransMedics Group Inc's market cap, and Gerdau S.A. Common Stock pays a 3.67% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gerdau S.A. Common Stock for 1 Days and TransMedics Group Inc for 24 Days on average.
| GGB | TMDX | |
|---|---|---|
Market Cap | $9.16B | $2.74B |
Volume | 16,238,936 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $5.17 | $150.42 |
52-Week Low | $3.15 | $61.99 |
Typical Hold Time | 1 Days | 24 Days |
Enterprise Value | $11.10B | $3.13B |
Dividend Yield | 3.67% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Gerdau is a steel producer with operations across the Americas. It makes long steel, specialty steel, and other products for construction and industrial markets.
Read more on GGB →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →